Navigation Links
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
Date:11/30/2009

SAN CARLOS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer. Dr. Masuoka will report directly to Nektar's President and Chief Executive Officer, Howard W. Robin.

"Lorianne's outstanding leadership and highly effective clinical development strategies have been instrumental in rapidly advancing Nektar's proprietary clinical pipeline, including the successful partnering of NKTR-118 with AstraZeneca," Robin said. "She has assembled a world-class Clinical Development team that has demonstrated its ability to efficiently and repeatedly move our high-value proprietary compounds through clinical development."

Dr. Masuoka has over 15 years of experience in clinical research and development in CNS, oncology, metabolic disease and immunology. As Senior Vice President and Chief Medical Officer, she will lead Clinical Development, Regulatory Affairs, Drug Safety, Clinical Pharmacology, Toxicology and Program Management.

Dr. Masuoka joined Nektar in August 2008 as Vice President of Clinical Development. Dr. Masuoka received her B.S. and M.D. from the University of California, Davis and completed her fellowship at the Yale School of Medicine. She is board certified in Neurology.

Dr. Randall Moreadith, Senior Vice President and Chief Development Officer, will be leaving the company for personal reasons. The company wishes to acknowledge his contributions over the past year.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for leading biopharmaceutical company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. Nektar recently entered into an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 program for the treatment of pain without constipation side effects. NKTR-102, PEGylated irinotecan, is currently being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's technology platform, Nektar's pipeline of product candidates in development, and Nektar's collaborations with third parties. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) Nektar's proprietary product candidates and those of its partners are in the early to mid-stage phases of clinical development and the risk of failure is high and can occur at any stage prior to regulatory approval; (ii) Nektar or its partners may not be able to successfully obtain regulatory approval for product candidates in development; (iii) Nektar's commercialization partners may not be successful in their sales and marketing efforts even if current product candidates successfully receive future regulatory approval in one or more markets; (iv) Nektar's patent applications for its technology platforms and proprietary or partner product candidates may not issue, patents that have issued may not be enforceable; and or intellectual property licenses from third parties may be required in the future; and (v) other important risks and uncertainties set forth in Nektar's most recent Quarterly Report on Form 10-Q filed on November 5, 2009 and its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2009. Actual results could differ materially from the forward-looking statements contained in this press release. Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

For more information on Nektar Therapeutics, please visit www.nektar.com

Jennifer Ruddock, 650-631-4954

SOURCE Nektar Therapeutics


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
2. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
3. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
4. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
7. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
8. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
9. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
10. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
11. Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 Dr. Vivek Ahuja , ... Ste phen Schmidt ... provider of cloud-based software solutions for life sciences, today announced key ... a wealth of insight to a growing business.  This will bolster ... George Phillips joined ArisGlobal in the position of Vice ...
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
(Date:4/27/2016)... TURIN, Italy , April 27, 2016 ... MR-guided linear accelerator (MR-linac) platform will be the focal ... annual meeting of the European Society for Radiotherapy & ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and ... a physician to clearly see the patient,s anatomy in ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 29, 2016 , ... Reltok Nasal Products proudly announces that Boston Medical Products, ... nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product ... a newly patented safety device secured by nasal surgeons onto the floor of the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... media enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, ... as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... and hospice software, outsourced billing and coding services, and Deyta Analytics, recently announced ... hospices providing the highest level of quality as measured from the caregiver’s point ...
(Date:4/29/2016)... ... April 29, 2016 , ... Pro3rd Grunge is a ... Film Studios’ lower thirds to introduce people, characters, and locations without having to set ... lines, accents, textures and many more design components. Simply select a preset and drag ...
(Date:4/28/2016)... ... 2016 , ... Monthly subscription boxes are all the rage, and "My Subscription ... the ZEN BOX , the aromatherapy subscription box. , ZEN BOX delivers three new ... frankincense) and one Zen Blend (like immune boost, sublime sleep or de-stress blends) ...
Breaking Medicine News(10 mins):